MannKind, a company focused on the development and commercialisation of inhaled therapeutic products, has announced that Steven B. Binder will retire from his position as Chief Financial Officer (CFO), effective April 22, 2024
Christopher Prentiss has been appointed as CFO, effective April 22, 2024. Prentiss will be a member of MannKind’s executive leadership team and will report to Michael Castagna, Chief Executive Officer (CEO).
Binder plans to remain at MannKind through the end of the year as Executive Vice President, Special Projects.